An innovative ALA-CART platform exhibits high efficacy against cancers.

The therapeutic efficacy of chimeric antigen receptor (CAR) T cells is compromised in antigen-low tumors due to poor sensitivity and insufficient persistence. In this issue of Cancer Cell, Pham-Danis et al. design the ALA-CART platform to improve CAR T cell sensitivity, persistence, differentiation, and cytotoxic function by enhancing LAT phosphorylation after low antigen stimulation.